Mural Oncology Plc (MURA) Price & Analysis

Compare

418 Followers

MURA Stock Chart & Stats

$2.04

$0.28(8.07%)

At close: Jan 08 4:00 PM EST

$2.04

$0.28(8.07%)

Day’s Range― - ―

52-Week Range$0.95 - $4.74

Previous CloseN/A

Volume157.34K

Average Volume (3M)143.46K

Market Cap

$36.04M

Enterprise Value-$31.23M

Total Cash (Recent Filing)$58.87M

Total Debt (Recent Filing)$3.55M

Price to Earnings (P/E)―

Beta-0.37

Next Earnings

Mar 31, 2026

EPS Estimate

-0.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding17,324,772

10 Day Avg. Volume71,484

30 Day Avg. Volume143,461

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.39

Price to Sales (P/S)0.00

P/FCF Ratio-0.42

Enterprise Value/Market Cap-0.87

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit16.01

Enterprise Value/Ebitda0.26

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Pipeline ProgressTopline data from cohort 2 of ARTISTRY-6 remains on-track for a potentially registrational readout evaluating nemvaleukin monotherapy in patients with mucosal melanoma.

Regulatory OpportunitiesA response rate between 20-25% would be considered clinically meaningful for patients and could support discussions with the FDA around a Biologics License Application (BLA) submission.

Bears Say

Clinical TrialsThe interim analysis of the Phase 3 ARTISTRY-7 study failed to show a statistically significant overall survival benefit over investigator’s choice chemotherapy in platinum-resistant ovarian cancer (PROC).

Workforce ReductionsThe company will undertake a reduction in its employee workforce of approximately 90%.

Mural Oncology Plc News

Xoma announces closing of transaction to acquire Mural Oncology

XOMA Royalty (XOMA) completed its previously announced acquisition of the entire issued and to be issued share capital...

19d ago

MURA

XOMA

Mural Oncology announces effectiveness of scheme of arrangement

Mural Oncology (MURA) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of...

19d ago

MURA

XOMA

Mural Oncology announces final cash consideration payable on acquisition close

Mural Oncology (MURA) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation...

28d ago

MURA

XOMA

Mural Oncology Plc Completes Acquisition by XRA 5 Corp.

Mural Oncology Plc ( ($MURA) ) just unveiled an update. On December 5, 2025, Mural Oncology Plc announced...

19d ago

MURA

Mural Oncology Approves Acquisition by XRA 5 Corp.

Mural Oncology Plc ( ($MURA) ) has issued an announcement. On October 24, 2025, Mural Oncology plc held...

2M ago

MURA

Mural Oncology shareholders approve acquisition by XRA 5 Corp.

Mural Oncology (MURA) announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural...

2M ago

MURA

XOMA

Mural Oncology Plc Announces Acquisition by XOMA Royalty Corporation

New activity is brewing for Mural Oncology Plc ( ($MURA) ). The company has submitted a Form DEFM14A...

3M ago

MURA

Mural Oncology Plc Announces Acquisition Agreement

Mural Oncology Plc ( ($MURA) ) just unveiled an announcement. On August 20, 2025, Mural Oncology plc entered...

4M ago

MURA

Mural Oncology PLC trading resumes

09:00 EDT Mural Oncology (MURA) PLC trading resumes Published first on TheFly – the ultimate source for real-time,...

4M ago

MURA

Mural Oncology to be acquired by XRA 5 Corp. for $2.035-$2.24 per share in cash

Mural Oncology (MURA) and XOMA Royalty (XOMA) entered into a definitive agreement pursuant to which XRA 5 Corp.,...

4M ago

MURA

XOMA

Mural Oncology PLC trading halted, news pending

08:25 EDT Mural Oncology (MURA) PLC trading halted, news pending Published first on TheFly – the ultimate source...

4M ago

MURA

Mural Oncology reports Q2 EPS ($2.78) vs ($1.86) last year

Following its announcement on April 15, 2025, Mural has taken steps to conserve its remaining cash, including the...

5M ago

MURA

Mural Oncology Plc Elects Directors at Annual Meeting

An update from Mural Oncology Plc ( ($MURA) ) is now available. On June 11, 2025, Mural Oncology...

6M ago

MURA

MURA Upcoming Earnings Report: What to Expect?

Mural Oncology Plc (MURA) is scheduled to report 1st quarter earnings on 05/20/2025. Regarding Q1 estimates, Wall Street...

7M ago

MURA

MURA FAQ

What was Mural Oncology Plc’s price range in the past 12 months?

Mural Oncology Plc lowest stock price was $0.95 and its highest was $4.74 in the past 12 months.

What is Mural Oncology Plc’s market cap?

Mural Oncology Plc’s market cap is $36.04M.

When is Mural Oncology Plc’s upcoming earnings report date?

Mural Oncology Plc’s upcoming earnings report date is Mar 31, 2026 which is in 97 days.

How were Mural Oncology Plc’s earnings last quarter?

Mural Oncology Plc released its earnings results on Nov 12, 2025. The company reported -$0.214 earnings per share for the quarter, beating the consensus estimate of -$0.59 by $0.376.

Is Mural Oncology Plc overvalued?

According to Wall Street analysts Mural Oncology Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Mural Oncology Plc pay dividends?

Mural Oncology Plc does not currently pay dividends.

What is Mural Oncology Plc’s EPS estimate?

Mural Oncology Plc’s EPS estimate is -0.37.

How many shares outstanding does Mural Oncology Plc have?

Mural Oncology Plc has 17,324,772 shares outstanding.

What happened to Mural Oncology Plc’s price movement after its last earnings report?

Mural Oncology Plc reported an EPS of -$0.214 in its last earnings report, beating expectations of -$0.59. Following the earnings report the stock price went down -0.952%.

Which hedge fund is a major shareholder of Mural Oncology Plc?

Currently, no hedge funds are holding shares in MURA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Mural Oncology Plc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-103.87%

Trailing 12-Months

Asset Growth

-62.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mural Oncology Plc

Mural Oncology Plc (MURA) is a biotechnology company focused on the development and commercialization of innovative cancer therapies. Operating within the pharmaceutical and healthcare sectors, Mural Oncology is dedicated to researching and delivering cutting-edge treatments that address unmet needs in oncology. The company's core products include targeted therapies and immuno-oncology treatments designed to improve patient outcomes and quality of life for those battling various forms of cancer.